Cited by 129Drug Transport and Resistance MechanismsBerberine and alkaloids researchDrug Solubulity and Delivery Systems

P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers

Maeng, Han-Joo, Yoo, Ho-Jung, Kim, In-Wha, Song, Im-Sook, Chung, Suk-Jae, Shim, Chang-Koo·2002·Journal of Pharmaceutical Sciences

Abstract

The objective of this study was to investigate the mechanisms by which berberine is transported in the secretory and absorptive directions across Caco-2 cell monolayers. The basolateral-to-apical (B-A) flux was 30-fold greater than the apical-to-basolateral flux and temperature dependent (i.e., drastic decrease at 4 degrees C compared with 37 degrees C). The above results suggest the involvement of a carrier-mediated active transport mechanism for the B-A transport of berberine. However, no significant concentration dependency for the permeability (P(app)) of berberine was observed for B-A transport over a concentration range of 5-300 microM, indicating that the K(m) value of berberine for the carrier system is greater than 300 microM. Well-documented P-glycoprotein (P-gp) substrates such as verapamil, daunomycin, and rhodamine123 inhibited the B-A flux of berberine, whereas tetraethylammonium and taurocholate did not, suggesting that P-gp is involved in the transport. For the case of daunomycin, the B-A flux, but not the apical-to-basolateral flux, was significantly increased after pretreatment of the cell monolayers with berberine. In addition, the uptake of 1 microM daunomycin into Caco-2 cells was decreased as a result of this pretreatment. These results suggest that the repeated administration of berberine may up-regulate P-gp functions in Caco-2 cells. If this occurs in the gastrointestinal epithelial cells, the repeated administration of berberine may reduce the gastrointestinal absorption of P-gp substrates including chemotherapeutic agents such as daunomycin.

Integrity signals

Registry

Crossref · 10.1002/jps.10268

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Local inhibition of CYP3A4 and P-glycoprotein in the intestinal wall can markedly increase the absorbed fraction of the victim drug, independently of berberine's modest plasma concentrations.

    “Local inhibition of CYP3A4 and P-glycoprotein in the intestinal wall can markedly increase the absorbed fraction of the victim drug, independently of berberine’s modest plasma concentrations [36,58].”
  • Berberine is both a substrate and an inhibitor of P-glycoprotein and can increase the intestinal absorption of its substrates.

    “Berberine is both a substrate and an inhibitor of P-glycoprotein (P-gp/MDR1), and can increase the intestinal absorption of its substrates [58,77,78]”
  • Because P-glycoprotein and CYP3A4 are frequently colocalized in the enterocyte and share substrates, simultaneous inhibition of both can have a multiplicative effect on bioavailability.

    “Because P-gp and CYP3A4 are frequently colocalized in the enterocyte and share substrates, simultaneous inhibition of both can have a multiplicative effect on bioavailability [58,64].”

Cites

Flagged first, then by citations

2 of the 32 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Maeng, H.-J., Yoo, H.-J., Kim, I.-W., Song, I.-S., Chung, S.-J., & Shim, C.-K.
Affiliations
Seoul National University (KR)
Corresponding author
Shim, Chang-Koo
Venue
Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2002-12
Volume
91
Issue
12
Pages
2614-2621
ISSN
0022-3549 (ISSN-L)
OpenAlex
W2091571409
Cited by
128
References
32
Citations by year
2026: 9 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 3 · 2020: 10 · 2019: 7 · 2018: 8 · 2017: 9 · 2016: 6 · 2015: 7 · 2014: 6 · 2013: 5 · 2012: 7
FWCI
1.18
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pharmaceutical Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Pharmacology › Berberine and alkaloids research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Keywords
berberine, P-glycoprotein, Caco-2 cell monolayers, intestinal drug transport, active transport, daunorubicin, gastrointestinal absorption, drug-drug interactions, verapamil, rhodamine 123
MeSH terms
Berberine, Biological Transport, Daunorubicin, Humans, Caco-2 Cells, ATP Binding Cassette Transporter, Subfamily B, Member 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review